Retatrutide in the UK: Is It Available, and What Can You Use Instead?
Takes less than 2 minutes to complete 100% online
Our Pricing
Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site. Prices shown are first-order prices with discount code Weightlossnew and were checked on 13 November 2026.
Mounjaro Weight Loss Injections (Tirzepatide) KwikPen
Wegovy (Semaglutide) Weight Loss Injection
Wegovy® Oral Tablets (Semaglutide Pill): PRE-ORDER
Retatrutide in the UK: What You Need to Know
Is Retatrutide Available in the UK?
No. Retatrutide is an investigational medicine from Eli Lilly. It has no marketing authorisation from the MHRA, so it cannot be lawfully prescribed, dispensed or sold in the UK, on the NHS or privately. Cured Pharmacy does not supply retatrutide, and there is no licensed retatrutide pen for UK patients to use.
Lilly has said it plans to submit retatrutide to the US FDA in the first quarter of 2027[3]. No UK approval date has been announced. A UK licence would need a separate MHRA assessment first, and NHS use would need NICE guidance after that.
Because retatrutide is unlicensed, this page does not give injection technique, doses or storage advice for it. Those details come from a medicine’s licence and patient information leaflet, and retatrutide has neither. If a website, seller or social post tells you how to inject a “retatrutide pen”, it is describing a product that has not been assessed for use in the UK.
What Is Retatrutide?
Retatrutide is a once-weekly injection being studied for weight loss. It is a triple agonist, which means it acts on three hormone receptors: GIP, GLP-1 and glucagon[1]. Mounjaro (tirzepatide) acts on two of these, GIP and GLP-1, and Wegovy (semaglutide) on one, GLP-1. Researchers are studying whether the added glucagon action helps with energy use as well as appetite.
What Have the Trials Shown?
In a Phase 2 trial of 338 adults with overweight or obesity, people taking the highest dose (12mg) lost an average of up to 24.2% of their body weight over 48 weeks[1].
Phase 3 results are now arriving. In TRIUMPH-1 (2,339 adults, 80 weeks), Lilly reported average weight loss of 17.6% at 4mg, 23.7% at 9mg and 25.0% at 12mg, compared with 3.9% on placebo[2]. Lilly also reported positive results from two further Phase 3 trials, TRIUMPH-2 and TRIUMPH-3, in July 2026[3]. These are topline announcements from the manufacturer, so treat them as early results.
Side effects reported
In TRIUMPH-1, the most common side effects at the highest dose were gastrointestinal: nausea (42.4% of participants), diarrhoea (32.0%), constipation (26.1%) and vomiting (25.3%)[2]. The long-term safety of retatrutide has not been established, which is one reason it must complete regulatory review before it can be used outside trials.
How does this compare with Mounjaro and Wegovy?
In the SURMOUNT-1 trial, tirzepatide 15mg gave an average weight loss of 20.9% over 72 weeks[5], and in STEP 1 semaglutide 2.4mg gave 14.9% over 68 weeks[6]. Retatrutide has not been compared directly with either medicine in a head-to-head trial, and the trials used different lengths, doses and people, so the figures cannot be compared like for like.
Why You Should Not Buy a Retatrutide Pen Online
Products sold online as “retatrutide”, often as pens, vials or “research” powders, are not licensed in the UK. The MHRA explains that licensed GLP-1 medicines have been assessed carefully for safety and effectiveness[4]. An unlicensed product has not, so its contents, strength and sterility cannot be checked, and it comes without the patient leaflet, prescriber oversight and safety monitoring that a licensed medicine has.
If you have already used an unlicensed injection and feel unwell, seek medical advice promptly. Call NHS 111 or speak to your GP or pharmacist, and call 999 in an emergency, for example with severe abdominal pain, repeated vomiting, difficulty breathing or swelling of the face or throat.
Licensed Weight Loss Treatments You Can Use Today
Several injectable treatments are licensed in the UK for weight management in adults who meet the criteria. A UK-registered prescriber reviews your health and history before recommending one.
| Treatment | Mechanism | Injection frequency | UK status | Starting price (first order) |
|---|---|---|---|---|
| Retatrutide | Triple GIP/GLP-1/glucagon agonist | Once weekly (in trials) | Not licensed, not available | Not available |
| Mounjaro (tirzepatide) | Dual GIP/GLP-1 agonist | Once weekly | MHRA-licensed | From £124.99 |
| Wegovy (semaglutide) | GLP-1 agonist | Once weekly | MHRA-licensed | From £69.00 |
| Saxenda (liraglutide) | GLP-1 agonist | Once daily | MHRA-licensed | From £48.00 |
Mounjaro and Wegovy are given once weekly and Saxenda once daily. All are prescription-only and are supplied only if a prescriber decides they are suitable for you after your consultation. If you already take one of them, keep taking it as prescribed and do not add another weight loss injection without speaking to your prescriber.
Scientific References
- Jastreboff, A. M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
- Pharmaceutical Journal. (2026). Phase III retatrutide study demonstrates 30% weight loss. https://pharmaceutical-journal.com/article/news/phase-iii-retatrutide-study-demonstrates-30-weight-loss [accessed 19 November 2026]
- Eli Lilly and Company. (2026, 23 July). Press release: positive topline results from the TRIUMPH-2 and TRIUMPH-3 Phase 3 trials, with a Biologics License Application for retatrutide planned for Q1 2027. https://investor.lilly.com/node/54721 [accessed 19 November 2026]
- Medicines and Healthcare products Regulatory Agency. GLP-1 medicines for weight loss and diabetes: what you need to know. GOV.UK. [accessed 19 November 2026]
- Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
- Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
Information on this page is for educational purposes only and is not medical advice. Retatrutide is currently investigational and not licensed for use in the UK. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.
Last reviewed: 19 November 2026 · Prices checked: 13 November 2026 · Next review: 19 May 2027
How it Works?
Select from our recommended UK-licensed medications.
1Choose your treatment

Select safe UK treatments. Quick answers.
2Answer quick questions

We will deliver direct to you as quickly as tomorrow.
3Get it delivered fast

Start Your Assessment For Weight Loss
Start your journey to better health today.
- Reviewed by UK-based prescribers
- Takes under 3 minutes
- Discreet Packaging
Start Your Journey To Better Health Today
Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.
Start My Assessment Log in to Your Account